Search
Sar9, Met (O2)11-Substance P
go.drugbank.com/drugs/DB05875InvestigationalSar9, Met (O2)11-Substance P is a neurokinin-1 receptor agonist.
Desogestrel
go.drugbank.com/drugs/DB00304ApprovedInvestigationalDesogestrel, a prodrug, is a third generation progestogen and hence, a member of the gonane family which was largely used in Europe before being approved in the US and Canada. It was firstly generated from a study that showed that 11-bet...
Categories: Hormonal Contraceptives for Systemic UseSulglicotide
go.drugbank.com/drugs/DB13299ExperimentalCategories: Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)Penamecillin
go.drugbank.com/drugs/DB13739ExperimentalCategories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseFexuprazan
go.drugbank.com/drugs/DB16078InvestigationalAbeprazan is under investigation in clinical trial NCT04341454 (Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Acute or Chronic Gastritis).
Categories: Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)Ramosetron
go.drugbank.com/drugs/DB09290InvestigationalCurrently, ramosetron is only approved for use Japan and in certain Southeast Asian countries. … Ramosetron is a _serotonin 5-HT3 receptor antagonist_ commonly employed to treat nausea and vomiting, in addition to certain diarrheal conditions.
Categories: Serotonin Receptor AntagonistsIsoquinoline, 7-(2-(3,6-dihydro-4-(3-(trifluoromethyl)phenyl)-1(2h)-pyridinyl)ethyl)-
go.drugbank.com/drugs/DB16204InvestigationalIsoquinoline, 7-(2-(3,6-dihydro-4-(3-(trifluoromethyl)phenyl)-1(2h)-pyridinyl)ethyl)- is under investigation in clinical trial NCT00545454 (Activity and Safety of Oral Administration of SSR150106XB for
Osoresnontrine
go.drugbank.com/drugs/DB16274InvestigationalOsoresnontrine is under investigation in clinical trial NCT02281773 (A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks
Sovleplenib
go.drugbank.com/drugs/DB17557InvestigationalSovleplenib is a novel, investigational, selective small molecule inhibitor for oral administration targeting spleen tyrosine kinase (Syk).